Keytruda Fails to Improve Overall Survival of Patients with Triple-Negative Breast Cancer, Phase 3 Trial Shows


May 24, 2019 - Disappointing news has just been just released about the promising new immunotherapy drug pembrolizumab (Keytruda), that did not show any overall survival advantage over conventional chemotherapy treatment in women with metastatic TNBC. There remains limited options for women diagnosed with this aggressive type of breast cancer, therefore it is imperative we keep working towards an effective targeted therapy for TNBC.

Read more here